These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24779514)

  • 1. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase.
    Currie KS; Kropf JE; Lee T; Blomgren P; Xu J; Zhao Z; Gallion S; Whitney JA; Maclin D; Lansdon EB; Maciejewski P; Rossi AM; Rong H; Macaluso J; Barbosa J; Di Paolo JA; Mitchell SA
    J Med Chem; 2014 May; 57(9):3856-73. PubMed ID: 24779514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
    Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
    Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rational design of highly selective spleen tyrosine kinase inhibitors.
    Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
    J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
    Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
    Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
    Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
    J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
    Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
    Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
    J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
    Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
    FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
    Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
    Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
    Lucas MC; Bhagirath N; Chiao E; Goldstein DM; Hermann JC; Hsu PY; Kirchner S; Kennedy-Smith JJ; Kuglstatter A; Lukacs C; Menke J; Niu L; Padilla F; Peng Y; Polonchuk L; Railkar A; Slade M; Soth M; Xu D; Yadava P; Yee C; Zhou M; Liao C
    J Med Chem; 2014 Mar; 57(6):2683-91. PubMed ID: 24520947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new Syk inhibitors through structure-based virtual screening.
    Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
    Belanger DB; Williams MJ; Curran PJ; Mandal AK; Meng Z; Rainka MP; Yu T; Shih NY; Siddiqui MA; Liu M; Tevar S; Lee S; Liang L; Gray K; Yaremko B; Jones J; Smith EB; Prelusky DB; Basso AD
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6739-43. PubMed ID: 20855207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
    Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
    Baluom M; Grossbard EB; Mant T; Lau DT
    Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and profiling of a selective and efficacious Syk inhibitor.
    Thoma G; Smith AB; van Eis MJ; Vangrevelinghe E; Blanz J; Aichholz R; Littlewood-Evans A; Lee CC; Liu H; Zerwes HG
    J Med Chem; 2015 Feb; 58(4):1950-63. PubMed ID: 25633741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents.
    Yamamoto N; Takeshita K; Shichijo M; Kokubo T; Sato M; Nakashima K; Ishimori M; Nagai H; Li YF; Yura T; Bacon KB
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1174-81. PubMed ID: 12766258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.